# Heron Therapeutics (HRTX) — Earnings

HRTX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/hrtx/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$0.03 |
| EPS estimate | −$0.01 |
| EPS surprise | −500.00% |
| Revenue surprise | −10.72% |
| Revenue | $37.7M |
| Revenue estimate | $42.2M |
| Reported | Aug 10, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/818033/000119312526341301/hrtx-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/2be7662b-b955-2f1e-e4bd-67093d555b9d.html) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 10, 2026 | −$0.01 | −$0.03 | -500.00% | $42.2M | $37.7M |
| Q1 2026 | May 11, 2026 | −$0.02 | −$0.04 | -71.67% | $36.7M | $34.7M |
| Q4 2025 | Feb 26, 2026 | −$0.02 | −$0.02 | 0.00% | $39.9M | $40.6M |
| Q3 2025 | Nov 4, 2025 | −$0.02 | −$0.10 | -566.67% | $39.0M | $38.2M |
| Q2 2025 | Aug 8, 2025 | −$0.01 | −$0.02 | -100.00% | $38.1M | $37.2M |
| Q1 2025 | May 6, 2025 | −$0.01 | $0.01 | 261.29% | $37.4M | $38.9M |
| Q4 2024 | Feb 27, 2025 | −$0.03 | $0.02 | 165.36% | $37.3M | $40.8M |
| Q3 2024 | Nov 12, 2024 | −$0.04 | −$0.03 | 20.84% | $36.8M | $32.8M |
| Q2 2024 | Aug 6, 2024 | −$0.04 | −$0.06 | -52.67% | $36.1M | $36.0M |
| Q1 2024 | May 7, 2024 | −$0.07 | −$0.02 | 73.15% | $33.0M | $34.7M |
| Q4 2023 | Mar 12, 2024 | −$0.15 | −$0.07 | 54.49% | $31.2M | $34.2M |
| Q3 2023 | Nov 14, 2023 | −$0.29 | −$0.17 | 41.88% | $32.6M | $31.4M |
| Q2 2023 | Aug 14, 2023 | −$0.22 | −$0.35 | -56.74% | $31.7M | $31.8M |
| Q1 2023 | May 11, 2023 | −$0.22 | −$0.27 | -24.77% | $29.7M | $29.6M |
| Q4 2022 | Mar 23, 2023 | −$0.32 | −$0.17 | 46.32% | $27.2M | $30.0M |
| Q3 2022 | Nov 8, 2022 | −$0.38 | −$0.38 | -1.06% | $27.0M | $26.6M |
| Q2 2022 | Aug 9, 2022 | −$0.54 | −$0.55 | -2.61% | $24.6M | $27.6M |
| Q1 2022 | May 9, 2022 | −$0.49 | −$0.63 | -29.90% | $22.6M | $23.5M |
| Q4 2021 | Feb 28, 2022 | −$0.58 | −$0.54 | 6.36% | $25.8M | $20.7M |
| Q3 2021 | Nov 3, 2021 | −$0.61 | −$0.51 | 16.12% | $25.5M | $23.2M |

## Frequently Asked Questions

### When did Heron Therapeutics (HRTX) last report earnings?

Heron Therapeutics last reported on Aug 10, 2026, covering fiscal Q2 2026.

### Did HRTX beat earnings estimates?

No. Heron Therapeutics reported EPS of −$0.03 for Q2 2026 against a −$0.01 estimate — a 500.00% miss.

### How much revenue did HRTX report last quarter?

Heron Therapeutics reported $37.7M in revenue for Q2 2026, against a consensus estimate of $42.2M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).